 |
 September 21, 2007 |
|
|
48-Week Selzentry Data Show Promise for Drug-Resistant HIV
Forty-eight weeks of therapy with Selzentry, combined with an optimized background regimen (OBR), is associated with greater viral load reductions and CD4 count increases compared with placebo among HIV-positive patients with limited treatment options due to drug resistance. |
|
| |
|
|
|
September 20, 2007 |
|
|
Selzentry Treatment Failure: The Impact of Tropism Changes
Approximately two thirds of patients participating in Phase III studies of Pfizer’s Selzentry (maraviroc) who experience treatment failure have HIV that has switched its tropism—a shift in the cellular receptors it uses to infect CD4s. |
|
| |
|
|
|
September 17, 2007 |
|
|
Lexiva and Kaletra Comparable in Long-Term Study
New data reported at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago suggest that Norvir (ritonavir)-boosted Lexiva (fosamprenavir) is similar to Kaletra (ritonavir-boosted lopinavir) in terms of long-term safety and effectiveness. |
|
| |
|
|
|
|
|
September 18, 2007 |
|
|
Heart Disease Risk Remains in Absence of HIV Treatment
There is growing evidence to suggest that untreated HIV infection may be a bigger threat to heart health than the lipid-raising effects of antiretroviral therapy. New data reported at the 47th ICAAC may explain help explain why this is. |
|
| |
|
|
|
September 17, 2007 |
|
|
High Risk of Peripheral Artery Disease in HIV
Not only do HIV-positive people face an increased risk of heart attacks and strokes due to clogging of the major blood vessels, but they may also be more likely to suffer from peripheral artery disease (PAD), which can affect other parts of the body.
|
|
| |
|
|
|
|
|
Peter Staley asks Dr. Sharon Walmsley what women need to know about HIV and antivirals, and gender differences needing more research. 
Peter Staley asks Dr. Joe Eron about the latest data on soon-to-be-approved Isentress and an entry inhibitor you might inject just once every other week. 
Peter Staley asks Dr. Joe Eron about the good news on a challenging drug -- newly-approved Selzentry -- and the very potent new protease inhibitor, Prezista. 
Peter Staley talks with Matt Sharp about his activism, his new regimen, and his facial lipo fix. 
Peter Staley interviews Jules Levin, an activist and survivor of hepatitis C and HIV coinfection, about the latest in HCV treatment and prevention. 
